Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04976231 · ClinicalTrials.gov registry record
MPS II Immunophenotyping
A clinical trial, sponsored by Duke University.
- Terminated
- Registry status
- 6
- Enrollment target
NCT04976231 is a clinical trial that was terminated before completion, run by Duke University. The registered enrollment target is 6 participants.
The verdict
NCT04976231 was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate how participant's body's immune system responds to idursulfase, an enzyme replacement therapy (ERT) and find out which types of immune cells are involved in causing untoward responses to the ERT so that the investigators can relate the level of immune response to the treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2024-04-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04976231
The ClinicalTrials.gov registry entry for NCT04976231 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04976231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04976231 about?
NCT04976231 is a clinical study titled "MPS II Immunophenotyping". The purpose of this study is to investigate how participant's body's immune system responds to idursulfase, an enzyme replacement therapy (ERT) and find out which types of immune cells are involved in causing untoward responses to the ERT so that the investigators can relate the level of immune resp...
What is the current status of trial NCT04976231?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2022-04-01. Estimated completion is 2024-04-26.
Who is sponsoring clinical trial NCT04976231?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.